MedTrace Logo

ePRO for Adjuvant Therapy of Colorectal Adenocarcinoma

NCT04069455 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2021-09-17

No results posted yet for this study

Summary

It is a multi-centric randomized controlled trial. The goal of this study is to observe the improvement of QoL using ePRO to manage patients with colorectal cancer who received Oxaliplatin-based adjuvant chemotherapy.The prognosis will also be studied.

Conditions

  • Colorectal Carcinoma

Interventions

OTHER

Electronic Patients Reported Outcomes

ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Kefeng Ding, MD · Second Affiliated Hospital, Zhejiang University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2021-10-01
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04069455 on ClinicalTrials.gov